

# VIVANZA BIOSCIENCES LIMITED

(Formerly known as Ijee Injectaa Limited)

Regd. Office: 702, 'A' Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.

Phone: 079 – 65410862 email: [info@iveeinjectaa.com](mailto:info@iveeinjectaa.com) CIN: L24110GJ1982PLC005057

---

May 30, 2016

To,  
Department of Corporate Services  
Bombay Stock Exchange Limited  
25<sup>th</sup> Floor, P. J. Tower,  
Dalal Street,  
Fort, Mumbai- 400 001.

Dear Sir/Madam,

## DECLARATION

I, Harshul Shah, Director of Vivanza Biosciences Limited having its registered office at 702, "A" Wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad – 380 006, hereby declare that, the Statutory Auditors of the Company, M/s GMCA & Co., Chartered Accountants (FRN: 109850W) have issued an Audit Report with unmodified opinion on audited financial results for the quarter/year ended on 31<sup>st</sup> March, 2016.

This declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2016 as amended by SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2016 vide notification no. SEBI/LAD-NRO/GN/2016-17/001 dated 25<sup>th</sup> May, 2016.

For Vivanza Biosciences Limited

*Harshul K. Shah*

Harshul K. Shah

Director

DIN: 01955747



**VIVANZA BIOSCIENCES LIMITED**

**(Formerly Known as IVEE INJECTAA LTD )**

Registered Office: 702 "A" wing, Ashoka Chambers, Rasala Marg, Ellisbridge, Ahmedabad 380 006.

CIN : L24110GJ1982PLC005057

**AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2016.**

Part I

(Rs. in Lacs except per share data)

Particulars	Quarter Ended			Year Ended	Year Ended
	31/03/2016	31/12/2015	31/03/2015	31/03/2016	31/03/2015
	Audited	Unaudited	Audited	Audited	Audited
1 Income from Operations					
(a) Net Income from Operations	0.00	0.00	0.00	0.00	0.00
(b) Other Operating Income	0.00	0.00	0.00	0.00	0.00
<b>Total Income from Operations (net)</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>	<b>0.00</b>
2 Expenses					
(a) Cost of Materials consumed	0.00	0.00	0.00	0.00	0.00
(b) Purchase of stock-in-trade	0.00	0.00	0.00	0.00	0.00
(c) Increase/Decrease in inventories of FG, WIP and stock-in-trade	0.00	0.00	0.00	0.00	0.00
(d) Employee benefits expense	0.00	0.00	0.00	0.00	0.00
(e) Depreciation and amortisation expense	0.00	0.00	0.00	0.00	0.00
(f) Other expenses	1.30	0.98	1.48	6.08	5.26
<b>Total Expenses</b>	<b>1.30</b>	<b>0.98</b>	<b>1.48</b>	<b>6.08</b>	<b>5.26</b>
Profit / (Loss) from operations before other income, finance costs and exceptional items (1-2)	-1.30	-0.98	-1.48	-6.08	-5.26
4 Other Income	0.05	0.00	0.00	0.05	0
Profit / (Loss) from ordinary activities before finance costs and exceptional items (3-4)	-1.25	-0.98	-1.48	-6.03	-5.26
6 Finance Costs	0.00	0.00	0.00	0.00	0.00
Profit / (Loss) from ordinary activities after finance costs but before exceptional items (5-6)	-1.25	-0.98	-1.48	-6.03	-5.26
8 Exceptional Items	0.00	0.00	0.00	0.00	0.00
9 Profit / (Loss) from ordinary activities before tax (7-8)	-1.25	-0.98	-1.48	-6.03	-5.26
10 Tax Expense	0.00	0.00	0.00	0.00	0.00
11 Net Profit / (Loss) from ordinary after tax (9-10)	-1.25	-0.98	-1.48	-6.03	-5.26
12 Extraordinary items (net of tax expenses)	0.00	0.00	0.00	0.00	0.00
13 Net Profit / (Loss) for the period (11-12)	-1.25	-0.98	-1.48	-6.03	-5.26
14 Share of Profit / ( Loss) of associates *	0.00	0.00	0.00	0.00	0.00
15 Minority Interest *	0.00	0.00	0.00	0.00	0.00
16 Net Profit / ( Loss ) after taxes , minority interest and share of profit / ( loss ) of associates ( 13 + 14 + 15 )*	-1.25	-0.98	-1.48	-6.03	-5.26
17 Paid-up equity share capital (Face value of ` 10/- each)	18.80	18.80	376.00	18.80	376.00
18 Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	(16.31)	(363.34)
19.i Earnings Per Share (before extraordinary items) (not annualised):					
(a) Basic	-0.66	-0.52	-0.04	-3.21	-0.14
(b) Diluted	-0.66	-0.52	-0.04	-3.21	-0.14
19.ii Earnings Per Share (after extraordinary items) (not annualised):					
(a) Basic	-0.66	-0.52	-0.04	-3.21	-0.14
(b) Diluted	-0.66	-0.52	-0.04	-3.21	-0.14


**Notes:**

- The above audited financial results was reviewed by the Audit Committee and taken on record By the Board of Directors at their meeting held on Monday 30 May 2016 .
- Company operates only in single segment i.e.pharmaceuticals related activities
- The Statutory Auditors have expressed an unqualified audit opinion on the quarter and year ending March 31, 2016.
- The previous quarter's/year's figures have been regrouped/rearranged wherever necessary to make it comparable with the current quarter/year.
- The figures of the last quarter are the balancing figures between audited figures in respect of full financial year and the published year to date figures upto the end of third quarter of the current financial year.


Date : 30/05/2016  
Place : Ahmedabad

For, VIVANZA BIOSCIENCES LIMITED

*H. Q. Shah*  
DIRECTOR



STATEMENT OF ASSETS AND LIABILITIES			
(Rs.in Lacs)			
Particulars		As at 31/03/2016	As at 31/03/2015
<b>A</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Shareholders' Funds</b>		
	(a) Share Capital	18.80	376.00
	(b) Reserves and Surplus	(16.31)	(359.38)
	<b>Sub-total - Shareholders' Funds</b>	<b>2.49</b>	<b>16.62</b>
<b>2</b>	<b>Non-current Liabilities</b>		
	(a) Long-term borrowings	-	-
	(b) Deferred Tax Liabilities (Net)	-	-
	(c) Other Long Term Liabilities	4.71	4.71
	<b>Sub-total - Non-current liabilities</b>	<b>4.71</b>	<b>4.71</b>
<b>3</b>	<b>Current Liabilities</b>		
	(a) Short -term borrowings	50.48	47.98
	(b) Trade Payables	-	-
	(c) Other Current Liabilities	5.93	4.54
	(d) Short-term Provisions	-	-
	<b>Sub-total - Current Liabilities</b>	<b>56.41</b>	<b>52.52</b>
	<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>63.61</b>	<b>73.85</b>
<b>B</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current Assets</b>		
	(a) Fixed Assets	-	-
	(b) Non-current Investments	0.25	0.25
	(c) Long-term loans and advances	59.33	59.33
	<b>Sub-total - Non-current Assets</b>	<b>59.58</b>	<b>59.58</b>
<b>2</b>	<b>Current Assets</b>		
	(a) Inventories	-	-
	(b) Trade Receivables	-	-
	(c) Cash and Cash Equivalents	3.00	5.14
	(d) Other current assets	1.03	9.12
	<b>Sub-total - Current Assets</b>	<b>4.02</b>	<b>14.27</b>
	<b>TOTAL - ASSETS</b>	<b>63.61</b>	<b>73.85</b>





# GMCA & Co.

## Chartered Accountants

Office : 101, "Parishram", 5-B, Rashmi Society, Nr. LG Showroom, Mithakali Six Road, Navrangpura, Ahmedabad-380 009. Ph. : 079-40037372, E-mail : gmca1973@gmail.com

### Auditor's Report on Standalone Quarterly Financial Results and Year to Date Results of Vivanza Biosciences Ltd. pursuant to Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015

#### Independent Auditors Report

To  
The Board of Directors,  
Vivanza Biosciences Ltd.

We have audited the quarterly financial results of Vivanza Biosciences Ltd. for the quarter ended 31<sup>st</sup> March 2016 and the year to date results for the period 01<sup>st</sup> April, 2015 to 31<sup>st</sup> March, 2016, attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015. These quarterly financial result as well as the year to date financial result have been prepared on the basis of the interim financial statements, which are the responsibility of the company's management. Our responsibility is to express an opinion on these financial results based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim Financial Reporting (AS 25 / And AS 34), prescribed, under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India.

We conducted our audit in accordance with the accounting standards generally accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial results are free of material misstatement(S). An audit includes examining, on a test basis, evidence supporting the amounts disclosed as financial results. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides a reasonable basis for our opinion.



In our opinion and to the best of our information and according to the explanations given to us these quarterly financial results as well as the year to date results:

- (i) are presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 in this regards; and
- (ii) Give a true and fair view of the net loss and other financial information for the quarter ended 31<sup>st</sup> March, 2016 as well as the year to date results for the period from 01<sup>st</sup> April, 2015 to 31<sup>st</sup> March, 2016.



For, G M C A & CO.  
Chartered Accountants  
FRN: 109850W



CA. Amin G Shaikh  
Partner  
Membership No: 108894

Place: Ahmedabad  
Date: 30.05.2016